CLINICAL AND THERAPEUTIC IMPLICATIONS OF SPROUTY2 FEEDBACK DYSREGULATION IN BRAF V600E MUTATION POSITIVE PAPILLARY THYROID CANCER

BACKGROUND: The BRAF V600E (BRAF+) mutation activates the MAPK/ERK pathway and may confer an aggressive phenotype in papillary thyroid cancer (PTC). However, clinically BRAF+PTC behavior varies from indolent to aggressive. SPRY2 is a negative feedback regulator of the MAPK/ERK pathway. We hypothesiz...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Dultz, Linda A., Dhar, Shumon, Ogilvie, Jennifer B., Heller, Keith S., Bar-Sagi, Dafna, Patel, Kepal N.
Formato: Artigo
Idioma:Inglês
Publicado: 2013
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4100696/
https://ncbi.nlm.nih.gov/pubmed/24094449
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.surg.2013.06.024
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares